Conference Activities & Talks -

Division display >> ／  All the affair displays  1 - 19 of about 19

  1. 浜野 しずか, 田中 圭祐, 高畑 篤, 坂東 夏菜, 島田 智仁, 吉藤 康太, 梅澤 佳央, 野上 彩子, 長尾 俊景, 山本 正英, 豊田 茂雄, 森 毅彦. 精巣原発悪性リンパ腫の治療成績. 日本血液学会学術集会 2024.10.01

  2. Satoru Aoyama, Ayako Nogami, Sadakatsu Ikeda, Takehiko Mori. Establishment of novel Chimeric Antigen Receptor (CAR) improving the target-cell-specificity.. The 85th Annual Meeting of the Japanese Society of Hematology 2023.10.13

  3. 青山 慧, 野上 彩子, 池田 貞勝, 森 毅彦. 複数抗原を認識することで標的細胞への選択性を制御する新規CAR-T細胞の開発. 日本血液学会学術集会 2023.10.01

  4. 本村 鷹多朗, 吉藤 康太, 貞任 大地, 野上 彩子, 齊藤 真貴子, 岡田 啓五, 青山 慧, 森 毅彦, 長尾 俊景. 新規GCB-DLBCL細胞株TMD13の樹立と特性評価(Establishment and characterization of TMD13. a novel GCB-type DLBCL cell line). 日本リンパ網内系学会会誌 2023.06.01

  5. Satoru Aoyama, Ayako Nogami, Sadakatsu Ikeda, Takehiko Mori. Novel protease-mediated double antigen recognizing Chimeric Antigen Receptor (CAR) enhances the directionality of CAR-T cell activity and improves target cell specificity.. Keystone symposia A4: Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy 2023.01.31

  6. Kota Yoshifuji, Yotaro Motomura, Makiko Saito, Ayako Nogami, Genji Kawade, Shiori Watabe, Kouhei Yamamoto, Takahiko Mori, Toshikage Nagao.. TPL2, a New Prognostic Factor and a Potential Therapeutic Target in ABC-DLBCL.. 64th ASH Annual Meeting and Exposition. 2022.12.11 New Orleans

  7. Satoru Aoyama, Ayako Nogami, Sadakatsu Ikeda, Takehiko Mori. Novel protease-mediated double antigen recognizing Chimeric Antigen Receptor (CAR) enhances directionality of CAR-T cell activity and improves target cell specificity.. 64th American Society of Hematology (ASH) annual Meeting and Exposition 2022.12.10

  8. 木村 萌, 西山 優, 上田 浩樹, 有松 朋之, 久保木 麻衣, 高畑 篤, 斎藤 真貴子, 東田 修二, 野上 彩子. Ravulizumab投与中PNH患者の周術期管理　総胆管結石症、急性胆管炎後の腹腔鏡下胆嚢摘出術(Perioperative management of a PNH patient treated with ravulizumab: in case of gallstone disease). 日本血液学会学術集会 2021.09.01

  9. Satoru Aoyama, Shunichiro Yasuda, Daisuke Watanabe, Hiroki Akiyama*, Yoshihiro Umezawa, Ayako Nogami, Osamu Miura and Norihiko Kawamat. A Protease-Mediated Regulatory Chimeric Antigen Receptor (CAR): “Double Arm” CAR System Improves Tumor-Cell-Specificity of CAR-T Cell Therapy.. The 62nd ASH Annual Meeting and Exposition 2020.12.05 San Diego, California

  10. Daisuke Watanabe, Ayako Nogami, Keigo Okada, Hiroki Akiyama, Yoshihiro Umezawa:, Toshikage Nagao, Osamu Miura. FLT3-ITD activates RSK1 to upregulate mTORC1 and eIF4B and to inhibit BAD and BIM. The 82nd Annual meeting of Japanese Society of Hematology 2020.10.10

  11. Ayako Nogami, Watanabe Daisuke, Keigo Okada, Hiroki Akiyama, Yoshihiro Umezawa, Toshikage Nagao, Shuji Tohdaand Osamu Miura. FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim. 60th ASH Annual Meeting and Exposition 2019.12.01 FL, Orange County Convention Center

  12. Ayako Nogami, Keigo Okada, Daisuke Watanabe, Hiroki Akiyama, Yoshihiro Umezawa, Shinya Ishida, Gaku Oshikawa, Shuji Tohda, Osamu Miura . Proteasome Inhibitors Downregulate the mTORC1/4EBP1/S6K/Mcl-1 Pathway Cooperatively with Inhibitors for The STAT5/Pim Kinase Pathway to Induce Apoptosis in FLT3-ITD-positive AML Cells. The 9th JSH International Symposium 2018 2018.07.28 Kyoto

  13. Hiroki Akiyama, Yoshihiro Umezawa, Keigo Okada, Shinya Ishida, Ayako Nogami, and Osamu Miura. Deubiquitinase Inhibitor WP1130 Blocks FLT3-ITD to Induce Apoptosis in Leukemic Cells. 59th ASH Annual Meeting & Exposition 2017.12.17 Atlanta, GA, USA

  14. Tomoko Yamashita, Hiroki Tsutsumi, Kota Yoshifuji, Tatsuya Saito, Yoshihiro Umezawa, Ayako Nogami, Ken Watanabe, Toshikage Nagao, Chizduko Sakashita, Masahide Yamamoto, Ayako Arai, Norihiko Kawamata, Osamu Miura, Tetsuya Fukuda. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 11q Deletion. 第79回日本血液学会学術集会 2017.10.22

  15. Keigo Okada, Ayako Nogami, Cheng Chen, Maho kawakami, Hiroki Akiyama, Shinya Ishida, Yoshihiro Umezawa, Osamu Miura. FLT3-ITD confers resistance to PI3K/Akt inhibitors by enhancing mTORC1/Mcl-1 pathway via Pim kinase. 第79回日本血液学会学術集会 2017.10.20

  16. Hiroki Akiyama，Yoshihiro Umezawa，Keigo Okada，Shinya Ishida，Ayako Nogami，Gaku Oshikawa，Osamu Miura. Deubiquitinase inhibitor WP1130 blocks JAK2-V617F and FLT3-ITD to induce apoptosis in leukemic cells. 第78回日本血液学会学術集会 2016.10.15 横浜

  17. Ayako Nogami, Keigo Okada, Gaku Oshikawa, Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa,Tetsuya Kurosu,Osamu Miura. FLT3-ITD Confers Resistance to Bortezomib By Protecting the mTOR/4EBP1 Pathway through Activation of STAT5 and Induction of Pim-1 Expression. 57th ASH Annual Meeting and Exposition 2015.12.05 Orange County Convention Center, Orlando

  18. Keigo Okada, Ayako Nogami, Gaku Oshikawa, Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa, Osamu Miura. FLT3-ITD confers resistance to PI3K/Akt inhibitors by inducing Pim kinases through STAT5 activation. 第77回日本血液学会学術集会 2015.10.18

  19. Yoshihiro Umezawa, Hiroki Akiyama, Keigo Okada, Shinya Ishida, Ayako Nogami, Gaku Oshikawa, Tetsuya Kurosu, Osamu Miura. PECAM−1 enhances SDF-1-induced chemotaxis mediated through activation of the PI3K/Akt/mTORC1 pathway. The 77th annual meeting of the japanese society of hematology 2015.10.17

< PREV - NEXT >

  • 1
To the head of this page.▲